Clinical activities of the epidermal growth factor receptor family inhibitors in breast cancer.
The epidermal growth factor (EGF) receptors play an important role in epithelial cell function. Upon stimulation of these receptors, an extensive network of signal transduction pathways is activated, including the PI3K/AKT and Ras/Erk pathways. This activation leads to cellular proliferation and survival. In breast cancer, the EGF receptor, ErbB2 (HER2/neu), can be amplified and over-expressed and this is associated with poor prognosis and drug resistance. Trastuzumab is a monoclonal antibody against ErbB2 and has demonstrated activity in the therapy of breast cancer patients with over-expression of ErbB2, both in the metastatic and adjuvant setting. Recently, a tyrosine kinase inhibitor, lapatinib, that targets both ErbB1 and ErbB2, has also shown activity in metastatic breast cancer. In this review, we will discuss the ErbB receptors and their signaling networks in breast cancer, as well as the clinical activities of trastuzumab and lapatinib in this disease.
Henson
Elizabeth S
ES
Manitoba Institute of Cell Biology, CancerCare Manitoba, University of Manitoba, Winnipeg, MB, Canada.
Johnston
James B
JB
Los
Marek
M
Gibson
Spencer B
SB
Cancer Res. 2006 Feb 1;66(3):1630-9
16452222
Cell. 1999 Mar 19;96(6):857-68
10102273
Cancer Res. 2006 Feb 1;66(3):1640-7
16452223
Oncogene. 1998 Mar;16(11):1493-9
9580112
Virchows Arch. 2005 May;446(5):475-82
15856292
Nat Cell Biol. 2001 Nov;3(11):973-82
11715018
Cancer Res. 2006 Jul 15;66(14):7245-52
16849573
J Clin Oncol. 1999 Sep;17(9):2639-48
10561337
Drugs Today (Barc). 2003;39 Suppl C:61-80
14988746
J Clin Oncol. 1996 Mar;14(3):737-44
8622019
J Clin Oncol. 2001 May 15;19(10):2587-95
11352950
EMBO J. 2000 Jul 3;19(13):3159-67
10880430
Cancer Res. 2005 Dec 1;65(23):11118-28
16322262
J Clin Oncol. 2004 Jul 15;22(14):2954-63
15254063
Breast Cancer. 2007;14(2):156-62
17485900
Nat Rev Cancer. 2005 May;5(5):341-54
15864276
Curr Med Chem. 2006;13(29):3483-92
17168718
Oncogene. 2007 May 28;26(25):3637-43
17530017
Cancer Cell. 2005 Apr;7(4):351-62
15837624
Oncologist. 2006 Nov-Dec;11(10):1047-57
17110623
J Cell Biochem. 2003 Aug 15;89(6):1177-92
12898516
Int J Radiat Oncol Biol Phys. 2004;59(2 Suppl):21-6
15142631
Semin Cancer Biol. 2003 Aug;13(4):267-73
14563121
Clin Lymphoma Myeloma. 2007 Mar;7 Suppl 2:S81-4
17382017
Cancer Res. 2005 Aug 15;65(16):7052-8
16103051
Biochem Biophys Res Commun. 2005 Jun 10;331(3):851-8
15865941
Curr Opin Chem Biol. 2005 Jun;9(3):325-31
15939336
Mol Cell. 2003 Sep;12(3):541-52
14527402
Clin Cancer Res. 1996 Jul;2(7):1215-9
9816290
J Natl Cancer Inst. 2007 Mar 7;99(5):348-9
17341725
Cancer Res. 2005 Jan 1;65(1):18-25
15665275
Mol Cell Biol. 1999 Sep;19(9):6195-206
10454566
Proc Natl Acad Sci U S A. 2006 May 16;103(20):7795-800
16682622
Drugs. 2007;67(9):1329-41
17547474
Curr Drug Targets. 2005 May;6(3):243-57
15857286
Oncogene. 2004 Jan 22;23(3):646-53
14737100
J Cell Mol Med. 2005 Jan-Mar;9(1):59-71
15784165
Oncogene. 2001 Mar 22;20(12):1465-75
11313890
Br J Cancer. 2004 Oct 18;91(8):1420-4
15365568
J Clin Oncol. 2002 Feb 1;20(3):719-26
11821453
J Natl Cancer Inst. 2007 May 2;99(9):694-705
17470737
Oncogene. 2002 Sep 12;21(41):6255-63
12214266
Exp Cell Res. 2002 Jan 15;272(2):192-8
11777344
Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):344-52
14751502
Mol Cancer Ther. 2007 Feb;6(2):667-74
17308062
Crit Rev Oncol Hematol. 2007 Apr;62(1):53-61
17324578
Cancer Res. 2004 Apr 1;64(7):2343-6
15059883
Ann Oncol. 2001 Jun;12(6):745-60
11484948
N Engl J Med. 2006 Dec 28;355(26):2733-43
17192538
J Clin Oncol. 2002 Apr 1;20(7):1800-8
11919237
Nature. 2002 Aug 29;418(6901):934
12198537
Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):19063-8
17148612
N Engl J Med. 2005 Oct 20;353(16):1659-72
16236737
N Engl J Med. 2001 Mar 15;344(11):783-92
11248153
N Engl J Med. 2005 Oct 20;353(16):1673-84
16236738
Physiol Rev. 1999 Jan;79(1):143-80
9922370
Mol Cell Biol. 1999 Oct;19(10):6845-57
10490623
Science. 1993 Nov 12;262(5136):1065-9
7694366